Source: Beximco Pharmaceuticals Ltd. (BXPHARMA) | FY 2023-24 | Page 146

### 31. Other comprehensive income/(expense)

Amount in Taka

| Particulars | Note | July 2023- June 2024 | July 2022- June 2023 |
|---|---|---|---|
| Fair value gain/(loss) on investment in listed shares | | - | (2,383,527) |
| **Total** | | **-** | **(2,383,527)** |

### 32. Earnings per share (EPS)

Amount in Taka

| Particulars | Note | July 2023- June 2024 | July 2022- June 2023 |
|---|---|---|---|
| (a) Earnings attributable to the owners of the Company | | 5,829,529,200 | 4,614,066,147 |
| (b) Weighted average number of shares outstanding during the year | | 446,112,089 | 446,112,089 |
| **Earnings per share (EPS)** | | **13.07** | **10.34** |

### 33. Net asset value (NAV) per share

Amount in Taka

| Particulars | Note | June 30, 2024 | June 30, 2023 |
|---|---|---|---|
| Total assets | | 69,344,022,640 | 69,156,783,247 |
| Less total liabilities | | (17,441,119,760) | (21,537,117,269) |
| Less non-controlling interest | | (3,952,938,136) | (3,938,962,240) |
| **Equity attributable to the owners of the Company** | | **47,949,964,744** | **43,680,703,738** |
| Number of ordinary shares | | 446,112,089 | 446,112,089 |
| **Net asset value (NAV) per share** | | **107.48** | **97.91** |

### 34. Net operating cash flow per share (NOCFPS)

Amount in Taka

| Particulars | Note | July 2023- June 2024 | July 2022- June 2023 |
|---|---|---|---|
| Net cash generated from operating activities | | 8,364,466,317 | 6,084,786,858 |
| Number of ordinary shares | | 446,112,089 | 446,112,089 |
| **Net operating cash flows per share (NOCFPS)** | | **18.75** | **13.64** |